迈威生物(688062.SH)：上半年净亏损5.51亿元

Core Viewpoint - Maiwei Biotech (688062.SH) reported a significant increase in revenue driven by drug sales, despite a substantial net loss for the period [1] Financial Performance - The company achieved operating revenue of 101.17 million yuan, primarily from drug sales amounting to 100.79 million yuan, representing a 53.50% increase compared to the same period last year [1] - The net profit attributable to shareholders was a loss of 551 million yuan [1] Research and Development - In the first half of 2025, the company's R&D investment reached 392.09 million yuan, which is a 21.72% increase compared to the first half of 2024 [1] - The high R&D expenses are attributed to the advancement of multiple clinical trials, particularly key registration clinical studies [1]